A Phase 2 interventional study of Toripalimab and Axitinib in Metastatic Non-Clear Cell Renal Cell Carcinoma and Metastatic Renal Medullary Carcinomas, sponsored by Fudan University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Fudan University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing toripalimab in Carcinoma, Renal Cell — 8 open to participants now, 11 under way, 1 of them phase 3. toripalimab · Carcinoma, Renal Cell.
Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, this one is the 8th largest by planned enrollment, is one of 5 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 13th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →8 of the 13 studies testing toripalimab in Carcinoma, Renal Cell are open now, in 1 country. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Jinling Hospital, China · Sites in China
Ages 18–80
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
ZHOU FANGJIAN · Sites in China
Ages 18–80
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
By country, each count listing its studies:
toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 9 most frequent:
Fudan University is the lead sponsor of 1,318 studies on the registry; 646 are open to participants now.
Fudan University has 7 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
1 of the studies testing toripalimab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05768464The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPostoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase II study will evaluate toripalimab plus axitinib in adults with previously untreated, synchronous metastatic non-clear cell renal cell carcinoma and renal medullary carcinomas whose primary kidney tumor remains in place and whose baseline tumor biopsy contains a tertiary lymphoid structure. All participants will receive toripalimab and axitinib for approximately 12 weeks. At Week 12, an independent multidisciplinary team will review treatment response, overall disease burden, fitness for surgery, technical resectability, and participant preference. Deferred cytoreductive nephrectomy will be performed only when it has an independent clinical indication; it is not mandatory and is not assigned at random. Participants who do not undergo surgery will remain in the study for clinical follow-up. The study will estimate the proportion of eligible surgical participants who remain free of progression or death 24 weeks after surgery and will evaluate whether the functional state of tertiary lymphoid structures in the treated primary tumor is associated with control of residual metastatic disease. Peripheral blood will be used to track T-cell and B-cell receptor clonotypes. Postoperative blood for this purpose will be collected only at 3 months, and disease progression.
MANTIS-RCC is an investigator-initiated, prospective, open-label, single-center, single-arm Phase II clinical and translational study. Candidate participants will undergo image-guided core biopsy of the intact primary renal tumor. Central pathology review will confirm non-clear cell renal cell carcinoma and renal medullary carcinoma, exclude any clear cell component, and confirm biopsy-detectable tertiary lymphoid structures using a prespecified morphologic and immunophenotypic definition.
Enrolled participants will receive toripalimab 240 mg by intravenous infusion every 3 weeks plus axitinib 5 mg orally twice daily for four planned cycles, corresponding to approximately 12 weeks of induction therapy. Imaging is required at baseline, Week 6, and Week 12. In the absence of progression or unacceptable toxicity, systemic therapy may continue after Week 12 and after surgery. Toripalimab may continue for up to approximately 2 years, and axitinib may continue until progression, unacceptable toxicity, withdrawal of consent, or an investigator decision that treatment should stop.
At Week 12, a multidisciplinary team that does not use the translational assay results will determine whether deferred cytoreductive nephrectomy is clinically appropriate. The decision will consider systemic disease control, performance status, operative risk, resectability of the primary tumor, metastatic burden, the clinical purpose of surgery, and participant preference. Surgery will not be performed solely to obtain research tissue. Participants with rapid progression, organ-threatening disease, unacceptable surgical risk, or a need to change systemic therapy will not undergo elective cytoreductive nephrectomy but will remain in the intention-to-treat clinical cohort.
The main postoperative analysis population will include participants who undergo protocol-defined deferred cytoreductive nephrectomy, have at least one measurable metastatic lesion that is not removed or locally treated at surgery, and are expected to resume the same systemic regimen. The surgery date is the landmark for postoperative time-to-event outcomes. Imaging obtained within 14 days before surgery provides the reference metastatic burden; imaging at 4 to 6 weeks after surgery confirms postoperative status but does not restart the progression-free survival clock.
The translational program integrates treated primary-tumor tissue, longitudinal imaging, and immune-repertoire measurements. The postoperative primary tumor will be used to construct a patient-level TLS Functional State Score. TCR sequencing is the primary repertoire analysis and BCR sequencing is supportive. Peripheral blood collected before surgery may include baseline, Week 3, Week 6, Week 12, and the day of surgery. After surgery, peripheral blood for TCR/BCR analysis will be collected only at Month 3, Month 6, and disease progression. The progression sample should be collected before a new systemic or local treatment when clinically feasible. The Month 3 samples will be used to characterize persistence of prespecified TLS-associated clonotypes; the progression sample will characterize loss, re-expansion, and newly detectable clonotypes.
The study is estimation-oriented. Thirty participants are planned. Enrollment may expand to a maximum of 40 only if an independent review confirms acceptable safety and feasibility and fewer than 20 participants are available for the postoperative residual-metastasis primary analysis, with ethics approval before expansion. The study does not test whether cytoreductive nephrectomy improves survival and does not include a TLS-negative comparison group or a randomized no-surgery control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive toripalimab plus axitinib for approximately 12 weeks. At Week 12, an independent multidisciplinary team determines whether deferred cytoreductive nephrectomy is clinically appropriate. Surgery is performed only for participants with clinical benefit, controlled systemic disease, acceptable operative risk, a safely resectable primary tumor, and an independent clinical indication. Participants who do not undergo surgery continue clinically appropriate systemic therapy and study follow-up.
Drug: Toripalimab · Drug: Axitinib · Procedure: Deferred Cytoreductive Nephrectomy
Toripalimab 240 mg is administered by intravenous infusion on Day 1 of each 3-week cycle for four planned induction cycles. Dose reduction is not permitted. In participants without progression or unacceptable toxicity, treatment may resume or continue after Week 12 and after surgery for a total duration of up to approximately 2 years, according to the protocol and clinical judgment.
Axitinib 5 mg is administered orally twice daily continuously during induction. Dose interruption and reduction to 3 mg twice daily and then 2 mg twice daily are permitted for toxicity. The drug is withheld before elective surgery and restarted after adequate wound healing. It may continue until progression, unacceptable toxicity, withdrawal, or investigator decision.
After Week 12 multidisciplinary review, radical or partial nephrectomy may be performed when clinically indicated and technically appropriate. The surgical approach is selected by the treating surgical team. The procedure is not mandatory, is not randomized, and is never performed solely to obtain research tissue.
24-Week Progression-Free Survival Rate From Deferred Cytoreductive Nephrectomy
Percentage of participants in the postoperative residual-metastasis primary analysis population who are alive and have not had central RECIST version 1.1 progression by 24 weeks after surgery. Starting a new systemic treatment or receiving local treatment for progression or symptoms in a residual metastatic lesion is counted as an event in the primary strategy.
Time frame: From the date of deferred cytoreductive nephrectomy through 24 weeks after surgery
Association Between the TLS Functional State Score and 24-Week Postoperative Progression-Free Survival
The patient-level TLS Functional State Score is derived from the treated primary renal tumor removed at surgery using prespecified pathology and multiplex immunofluorescence features. Association with 24-week postoperative progression-free survival is summarized as the odds ratio per 1-standard-deviation increase in the score, with a 95% confidence interval.
Time frame: Tumor tissue collected at surgery; clinical outcome assessed through 24 weeks after surgery
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.
Of 184 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 98. This study's planned 15 months is below that.
Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Toripalimab · Axitinib